Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw.

Kitagawa Y, Ohga N, Asaka T, Sato J, Hata H, Helman J, Tsuboi K, Amizuka N, Kuge Y, Shiga T.

Jpn Dent Sci Rev. 2019 Nov;55(1):65-70. doi: 10.1016/j.jdsr.2018.12.001. Epub 2019 Mar 15. Review.

2.

The identification of autoantigens in mucous membrane pemphigoid using immortalized oral mucosal keratinocytes.

Kamaguchi M, Iwata H, Miyauchi T, Ujiie H, Ujiie I, Nomura T, Ohga N, Shimizu H, Kitagawa Y.

J Oral Pathol Med. 2019 Jan;48(1):60-67. doi: 10.1111/jop.12780. Epub 2018 Oct 24.

PMID:
30222210
3.

Mucosal substrates successfully identify the autoantigen in a case of mucous membrane pemphigoid.

Kamaguchi M, Iwata H, Ujiie H, Ohga N, Kitagawa Y, Shimizu H.

J Dtsch Dermatol Ges. 2018 Aug;16(8):1032-1034. doi: 10.1111/ddg.13618. No abstract available.

PMID:
30117705
4.

Schleimhautsubstrate identifizieren erfolgreich das Autoantigen bei einem Schleimhautpemphigoid.

Kamaguchi M, Iwata H, Ujiie H, Ohga N, Kitagawa Y, Shimizu H.

J Dtsch Dermatol Ges. 2018 Aug;16(8):1032-1035. doi: 10.1111/ddg.13618_g. No abstract available.

PMID:
30117697
5.

Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis.

Ohga N, Sato J, Asaka T, Morimoto M, Yamazaki Y, Kitagawa Y.

J Oral Sci. 2018;60(1):159-162. doi: 10.2334/josnusd.17-0027.

6.

Hypoxic volume evaluated by 18F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: preliminary analyses.

Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, Shiga T, Satoh A, Tamaki N.

Int J Oral Maxillofac Surg. 2018 May;47(5):553-560. doi: 10.1016/j.ijom.2017.09.007. Epub 2017 Oct 10.

PMID:
29030021
7.

Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance.

Hida K, Maishi N, Akiyama K, Ohmura-Kakutani H, Torii C, Ohga N, Osawa T, Kikuchi H, Morimoto H, Morimoto M, Shindoh M, Shinohara N, Hida Y.

Cancer Sci. 2017 Nov;108(11):2195-2203. doi: 10.1111/cas.13388. Epub 2017 Sep 17.

8.

18F-Fluoromisonidazole positron emission tomography (FMISO-PET) may reflect hypoxia and cell proliferation activity in oral squamous cell carcinoma.

Sato J, Kitagawa Y, Watanabe S, Asaka T, Ohga N, Hirata K, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep;124(3):261-270. doi: 10.1016/j.oooo.2017.05.506. Epub 2017 Jun 8.

PMID:
28734696
9.

ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells.

Hojo T, Maishi N, Towfik AM, Akiyama K, Ohga N, Shindoh M, Hida Y, Minowa K, Fujisawa T, Hida K.

Oncotarget. 2017 Jul 11;8(28):45484-45495. doi: 10.18632/oncotarget.17567.

10.

miR-145 promoted anoikis resistance in tumor endothelial cells.

Hida K, Kawamoto T, Maishi N, Morimoto M, Akiyama K, Ohga N, Shindoh M, Shinohara N, Hida Y.

J Biochem. 2017 Aug 1;162(2):81-84. doi: 10.1093/jb/mvx033.

PMID:
28510655
11.

Vasohibin-1 as a Novel Prognostic Factor for Head and Neck Squamous Cell Carcinoma.

Torii C, Hida Y, Shindoh M, Akiyama K, Ohga N, Maishi N, Ohiro Y, Ono M, Totsuka Y, Kitagawa Y, Tei K, Sato Y, Hida K.

Anticancer Res. 2017 Mar;37(3):1219-1225.

PMID:
28314285
12.

Unusual maxillary osteoblastic and osteolytic lesions presenting as an initial manifestation of childhood acute myeloid leukemia: A case report.

Shimizu R, Ohga N, Miyakoshi M, Asaka T, Sato J, Kitagawa Y.

Quintessence Int. 2017;48(2):149-153. doi: 10.3290/j.qi.a37383.

PMID:
27981267
13.

Tumor endothelial cells express high pentraxin 3 levels.

Hida K, Maishi N, Kawamoto T, Akiyama K, Ohga N, Hida Y, Yamada K, Hojo T, Kikuchi H, Sato M, Torii C, Shinohara N, Shindoh M.

Pathol Int. 2016 Dec;66(12):687-694. doi: 10.1111/pin.12474. Epub 2016 Nov 14.

PMID:
27862647
14.

Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study.

Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y.

Clin Oral Investig. 2017 Sep;21(7):2165-2172. doi: 10.1007/s00784-016-2004-z. Epub 2016 Nov 11.

PMID:
27837344
15.

Elimination of oral candidiasis may increase stimulated whole salivary flow rate.

Ohga N, Yamazaki Y, Sato J, Asaka T, Morimoto M, Hata H, Satoh C, Kitagawa Y.

Arch Oral Biol. 2016 Nov;71:129-133. doi: 10.1016/j.archoralbio.2016.06.028. Epub 2016 Aug 3.

PMID:
27497081
16.

Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan.

Maishi N, Ohba Y, Akiyama K, Ohga N, Hamada J, Nagao-Kitamoto H, Alam MT, Yamamoto K, Kawamoto T, Inoue N, Taketomi A, Shindoh M, Hida Y, Hida K.

Sci Rep. 2016 Jun 13;6:28039. doi: 10.1038/srep28039.

17.

Differences in sequential posttreatment salivary IL-6 levels between patients with and patients without locoregional recurrences of oral squamous cell carcinoma: Part III of a cohort study.

Sato J, Ohuchi M, Wada M, Ohga N, Asaka T, Yoshikawa K, Miyakoshi M, Hata H, Satoh A, Kitagawa Y.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Dec;120(6):751-60.e2. doi: 10.1016/j.oooo.2015.08.016. Epub 2015 Sep 5.

PMID:
26548727
18.

Evaluation of the level of progression of extracapsular spread for cervical lymph node metastasis in oral squamous cell carcinoma.

Yamada S, Yanamoto S, Otani S, Hasegawa T, Miyakoshi M, Minamikawa T, Ohga N, Kamata T, Komori T, Kitagawa Y, Kurita H, Umeda M.

Int J Oral Maxillofac Surg. 2016 Feb;45(2):141-6. doi: 10.1016/j.ijom.2015.09.005. Epub 2015 Oct 2.

PMID:
26439759
19.

CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property.

Yamada K, Maishi N, Akiyama K, Towfik Alam M, Ohga N, Kawamoto T, Shindoh M, Takahashi N, Kamiyama T, Hida Y, Taketomi A, Hida K.

Int J Cancer. 2015 Dec 15;137(12):2825-36. doi: 10.1002/ijc.29655. Epub 2015 Jul 2.

20.

Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis.

Ohga N, Yamazaki Y, Tsuboi K, Kitagawa Y.

Quintessence Int. 2015 Jul-Aug;46(7):621-6. doi: 10.3290/j.qi.a33528.

PMID:
25646168
21.

Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.

Akiyama K, Maishi N, Ohga N, Hida Y, Ohba Y, Alam MT, Kawamoto T, Ohmura H, Yamada K, Torii C, Shindoh M, Hida K.

Am J Pathol. 2015 Feb;185(2):572-80. doi: 10.1016/j.ajpath.2014.10.017. Epub 2014 Dec 8.

22.

Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype.

Ohmura-Kakutani H, Akiyama K, Maishi N, Ohga N, Hida Y, Kawamoto T, Iida J, Shindoh M, Tsuchiya K, Shinohara N, Hida K.

PLoS One. 2014 Dec 1;9(12):e113910. doi: 10.1371/journal.pone.0113910. eCollection 2014.

23.

Construction of an aptamer modified liposomal system targeted to tumor endothelial cells.

Ara MN, Matsuda T, Hyodo M, Sakurai Y, Ohga N, Hida K, Harashima H.

Biol Pharm Bull. 2014;37(11):1742-9.

24.

Suprabasin as a novel tumor endothelial cell marker.

Alam MT, Nagao-Kitamoto H, Ohga N, Akiyama K, Maishi N, Kawamoto T, Shinohara N, Taketomi A, Shindoh M, Hida Y, Hida K.

Cancer Sci. 2014 Dec;105(12):1533-40. doi: 10.1111/cas.12549. Epub 2014 Nov 5.

25.

Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells.

Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H.

Int J Pharm. 2014 Nov 20;475(1-2):227-37. doi: 10.1016/j.ijpharm.2014.08.048. Epub 2014 Aug 26.

PMID:
25169077
26.

An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.

Ara MN, Matsuda T, Hyodo M, Sakurai Y, Hatakeyama H, Ohga N, Hida K, Harashima H.

Biomaterials. 2014 Aug;35(25):7110-20. doi: 10.1016/j.biomaterials.2014.04.087. Epub 2014 May 27.

27.

Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand.

Ara MN, Hyodo M, Ohga N, Akiyama K, Hida K, Hida Y, Shinohara N, Harashima H.

Cancer Med. 2014 Aug;3(4):825-34. doi: 10.1002/cam4.260. Epub 2014 May 9.

28.

Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.

Otsubo T, Hida Y, Ohga N, Sato H, Kai T, Matsuki Y, Takasu H, Akiyama K, Maishi N, Kawamoto T, Shinohara N, Nonomura K, Hida K.

Cancer Sci. 2014 May;105(5):560-7. doi: 10.1111/cas.12394. Epub 2014 Apr 19.

29.

Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment.

Kondoh M, Ohga N, Akiyama K, Hida Y, Maishi N, Towfik AM, Inoue N, Shindoh M, Hida K.

PLoS One. 2013 Nov 15;8(11):e80349. doi: 10.1371/journal.pone.0080349. eCollection 2013.

30.

RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.

Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H.

J Control Release. 2014 Jan 10;173:110-8. doi: 10.1016/j.jconrel.2013.10.003. Epub 2013 Oct 11.

31.

Lysyl oxidase secreted by tumour endothelial cells promotes angiogenesis and metastasis.

Osawa T, Ohga N, Akiyama K, Hida Y, Kitayama K, Kawamoto T, Yamamoto K, Maishi N, Kondoh M, Onodera Y, Fujie M, Shinohara N, Nonomura K, Shindoh M, Hida K.

Br J Cancer. 2013 Oct 15;109(8):2237-47. doi: 10.1038/bjc.2013.535. Epub 2013 Sep 17.

32.

A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence.

Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H.

Int J Pharm. 2013 Nov 1;456(1):195-201. doi: 10.1016/j.ijpharm.2013.07.068. Epub 2013 Aug 7.

33.

Heterogeneity of tumor endothelial cells.

Hida K, Ohga N, Akiyama K, Maishi N, Hida Y.

Cancer Sci. 2013 Nov;104(11):1391-5. doi: 10.1111/cas.12251. Epub 2013 Sep 12. Review.

34.

Application of POLARIC™ fluorophores in an in vivo tumor model.

Maishi N, Kawamoto T, Ohga N, Yamada K, Akiyama K, Yamamoto K, Osawa T, Hida Y, Hida K.

Oncol Rep. 2013 Oct;30(4):1695-700. doi: 10.3892/or.2013.2620. Epub 2013 Jul 18.

35.

The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.

Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H.

Biomaterials. 2013 Jul;34(22):5617-27. doi: 10.1016/j.biomaterials.2013.03.094. Epub 2013 Apr 24.

36.

An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid.

Yamada Y, Hashida M, Hayashi Y, Tabata M, Hyodo M, Ara MN, Ohga N, Hida K, Harashima H.

J Pharm Sci. 2013 Sep;102(9):3119-27. doi: 10.1002/jps.23480. Epub 2013 Mar 7.

PMID:
23471825
37.

The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma.

Akiyama K, Ohga N, Maishi N, Hida Y, Kitayama K, Kawamoto T, Osawa T, Suzuki Y, Shinohara N, Nonomura K, Shindoh M, Hida K.

Pathol Int. 2013 Jan;63(1):37-44. doi: 10.1111/pin.12031.

PMID:
23356224
38.

Tumour endothelial cells acquire drug resistance in a tumour microenvironment.

Hida K, Akiyama K, Ohga N, Maishi N, Hida Y.

J Biochem. 2013 Mar;153(3):243-9. doi: 10.1093/jb/mvs152. Epub 2013 Jan 3. Review.

PMID:
23293323
39.

Development of a novel DNA aptamer ligand targeting to primary cultured tumor endothelial cells by a cell-based SELEX method.

Ara MN, Hyodo M, Ohga N, Hida K, Harashima H.

PLoS One. 2012;7(12):e50174. doi: 10.1371/journal.pone.0050174. Epub 2012 Dec 4.

40.

Intra-articular fracture of the mandibular condyle: a case report.

Yura S, Ohga N, Ooi K, Izumiyama Y.

Cranio. 2012 Jul;30(3):227-30.

PMID:
22916676
41.

Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.

Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H.

J Control Release. 2012 Aug 20;162(1):225-32. doi: 10.1016/j.jconrel.2012.06.019. Epub 2012 Jun 20.

42.

CXCR7: a novel tumor endothelial marker in renal cell carcinoma.

Maishi N, Ohga N, Hida Y, Akiyama K, Kitayama K, Osawa T, Onodera Y, Shinohara N, Nonomura K, Shindoh M, Hida K.

Pathol Int. 2012 May;62(5):309-17. doi: 10.1111/j.1440-1827.2012.02792.x. Epub 2012 Feb 21.

PMID:
22524658
43.

Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis.

Kawamoto T, Ohga N, Akiyama K, Hirata N, Kitahara S, Maishi N, Osawa T, Yamamoto K, Kondoh M, Shindoh M, Hida Y, Hida K.

PLoS One. 2012;7(3):e34045. doi: 10.1371/journal.pone.0034045. Epub 2012 Mar 30.

44.

Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner.

Osawa T, Ohga N, Hida Y, Kitayama K, Akiyama K, Onodera Y, Fujie M, Shinohara N, Shindoh M, Nonomura K, Hida K.

Cancer Sci. 2012 Jun;103(6):1038-44. doi: 10.1111/j.1349-7006.2012.02261.x. Epub 2012 Apr 17.

45.

Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.

Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T, Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, Shinohara N, Shindoh M, Hida K.

Br J Cancer. 2012 Mar 13;106(6):1214-23. doi: 10.1038/bjc.2012.59. Epub 2012 Feb 28.

46.

Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.

Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, Inoue N, Shindoh M, Hida K.

Am J Pathol. 2012 Mar;180(3):1283-93. doi: 10.1016/j.ajpath.2011.11.029. Epub 2012 Jan 13.

PMID:
22245726
47.

Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors.

Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, Ohmura H, Shinohara N, Nonomura K, Shindoh M, Hida K.

Am J Pathol. 2012 Mar;180(3):1294-307. doi: 10.1016/j.ajpath.2011.11.035. Epub 2012 Jan 12.

PMID:
22245217
48.

Altered angiogenesis in the tumor microenvironment.

Hida K, Kawamoto T, Ohga N, Akiyama K, Hida Y, Shindoh M.

Pathol Int. 2011 Nov;61(11):630-7. doi: 10.1111/j.1440-1827.2011.02726.x. Epub 2011 Oct 10. Review.

PMID:
22029673
49.

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.

Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H.

J Control Release. 2011 Jul 30;153(2):141-8. doi: 10.1016/j.jconrel.2011.03.012. Epub 2011 Apr 5.

50.

Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.

Muraki C, Ohga N, Hida Y, Nishihara H, Kato Y, Tsuchiya K, Matsuda K, Totsuka Y, Shindoh M, Hida K.

Int J Cancer. 2012 Jan 1;130(1):59-70. doi: 10.1002/ijc.25976. Epub 2011 Apr 20.

Supplemental Content

Support Center